soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm 🚨 25 mg delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Oral Semaglutide and Cardiovascular Outcomes

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes

These metabolic effects can have positive implications beyond weight loss and blood sugar control, contributing to overall metabolic health [3]

OZEMPIC should be injected once a week , at any time of day, with or without food

However, avoid applying topical corticosteroids to large body surface areas or for extended periods without medical supervision

This ensures not only that the medication itself is safe and appropriate, but that patients receive the wider clinical support needed to achieve sustainable, long-term outcomes. Dangers to patients Dix also listed out the other major dangers these medicines could pose to the public